Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Studien-Informationen Einschlusskriterien Studien-Rationale Geprüfte Regime

Rekrutierend

NCT-Nummer:
NCT04109755

Studienbeginn:
Juni 2020

Letztes Update:
30.09.2021

Wirkstoff:
Pembrolizumab

Indikation (Clinical Trials):
Rectal Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
University Hospital, Geneva

Collaborator:
-

Kontakt

Thibaud Kössler, MD PhD
Kontakt:
Phone: +41 (0)22 372 77 68
E-Mail: thibaud.kossler@hcuge.ch» Kontaktdaten anzeigen

Sandra Bettinelli Riccardi, PhD
Kontakt:
Phone: +41223722903
E-Mail: Sandra.BettinelliRiccardi@hcuge.ch» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Hôpitaux Universitaires de Genève
1205 Geneva
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Thibaud Kössler, MD PhD
E-Mail: thibaud.kossler@hcuge.ch» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

This project investigates the clinical and biological impact of combining immunotherapy

(pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant

treatment of localised microsatellite stable (MSS) rectal cancer.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Male/female participants who are at least 18 years of age on the day of signing

informed consent with histologically confirmed diagnosis of rectal adenocarcinoma will

be enrolled in this study.

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Evaluation of ECOG is to be performed within 7 days prior to the date of allocation.

- Patients with previously untreated localized T3-T4 N0 or T any or N1-2, M0 rectal

adenocarcinoma.

- Tumour must be microsatellite stable (MSS).

- A multi-disciplinary tumour board should recommend neo-adjuvant short course

radiotherapy and surgery.

- Have provided archival tumour tissue sample or newly obtained core or excisional

biopsy of a tumour lesion not previously irradiated. Formalin-fixed paraffin embedded

(FFPE) tissue blocks are preferred.

- Have adequate organ function as defined in the following table. Specimens must be

collected within 10 days prior to the start of study treatment.

Exclusion Criteria:

- Has a microsatellite instable tumour (MSI-High).

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with

an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,

OX 40, CD137).

- Has received for the same disease prior systemic anti-cancer therapy including

investigational agents prior to starting pembrolizumab. Note: If participant received

major surgery, they must have recovered adequately from the toxicity and/or

complications from the intervention prior to starting study treatment.

- Has received prior radiotherapy for the same disease. If treated with radiotherapy for

another disease, participants must have recovered from all radiation-related

toxicities, not require corticosteroids, and not have had radiation pneumonitis.

- Has received a live vaccine within 30 days prior to the first dose of study drug.

Examples of live vaccines include, but are not limited to, the following: measles,

mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus

Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection

are generally killed virus vaccines and are allowed; however, intranasal influenza

vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

- Is currently participating in or has participated in a study of an investigational

agent or has used an investigational device within 4 weeks prior to the first dose of

study treatment. Note: Participants who have entered the follow-up phase of an

investigational study may participate as long as it has been 4 weeks after the last

dose of the previous investigational agent.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy

(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of

immunosuppressive therapy within 7 days prior to the first dose of study drug.

- Has a known additional malignancy that is progressing or has required active treatment

within the past 3 years. Note: Participants with basal cell carcinoma of the skin,

squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,

cervical cancer in situ) that have undergone potentially curative therapy are not

excluded.

- Has known active CNS metastases and/or carcinomatous meningitis. Participants with

previously treated brain metastases may participate provided they are radiologically

stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging

(note that the repeat imaging should be performed during study screening), clinically

stable and without requirement of steroid treatment for at least 14 days prior to

first dose of study treatment.

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

- Has active autoimmune disease that has required systemic treatment in the past 2 years

(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive

drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid

replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a

form of systemic treatment.

- Has a history of (non-infectious) pneumonitis that required steroids or has current

pneumonitis.

- Has an active infection requiring systemic therapy.

- Has a known history of Human Immunodeficiency Virus (HIV).

- Has a known history of Hepatitis B virus (defined as Hepatitis B surface antigen

[HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA > 1.5E1 is

detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required

unless mandated by local health authority.

- Has a known history of active TB (Bacillus Tuberculosis).

- Has a history or current evidence of any condition, therapy, or laboratory abnormality

that might confound the results of the study, interfere with the subject's

participation for the full duration of the study, or is not in the best interest of

the subject to participate, in the opinion of the treating investigator.

- Has known psychiatric or substance abuse disorders that would interfere with

cooperation with the requirements of the trial.

Studien-Rationale

Primary outcome:

1. Tumour regression grade (Time Frame - 12 weeks after start):
To assess the tumour regression grade (TRG) after short course radiotherapy when given together with pembrolizumab, using the Mandard regression grade score

Secondary outcome:

1. Tolerability and safety (Time Frame - 5 years):
To assess tolerability and safety of pembrolizumab given with short course radiotherapy before surgery, using the common terminology criteria for adverse events (CTCAE) Version 4.0

2. Overall Survival (Time Frame - 5 years):
To estimate overall survival (OS), defined as the time between the date of the study entry and the date of death due to any cause. Subjects who have not died at the time of last known follow-up will be censored.

3. Disease-free survival (Time Frame - 3 years):
To estimate disease-free survival (DFS), defined as the time between the date of the study entry and the date of recurrence, second primary cancer, or death without evidence of recurrence or second primary cancer.

4. Locoregional relapse-free survival (Time Frame - 5 years):
To estimate locoregional relapse-free survival (LRRFS), defined as the time between the date of the surgery and local or regional recurrence. LRRFS is evaluated in patients who had an R0 resection only

5. Distant metastasis-free survival (Time Frame - 5 years):
To estimate distant metastasis-free survival (DMFS), defined as the time between the date of the surgery and metastatic recurrence.

6. EORTC QLQ-C30 (Time Frame - 30 months):
European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-C30

7. EORTC QLQ-CR29 (Time Frame - 30 months):
European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-CR29

Geprüfte Regime

Pembrolizumab:
5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery

Quelle: ClinicalTrials.gov

Sie können folgenden Inhalt einem Kollegen empfehlen:

"Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!